These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
373 related articles for article (PubMed ID: 25975689)
1. [Association between BRAF V600E mutation and central lymph node metastasis in patients with papillary thyroid carcinoma]. Shi C; Qin H; Ding C; Sun Y; Lyu Y; Shi T Zhonghua Zhong Liu Za Zhi; 2015 Feb; 37(2):123-7. PubMed ID: 25975689 [TBL] [Abstract][Full Text] [Related]
2. Correlation between the BRAF V600E mutation status and the clinicopathologic features of papillary thyroid carcinoma. Shi CL; Sun Y; Ding C; Lv YC; Qin HD Genet Mol Res; 2015 Jul; 14(3):7377-85. PubMed ID: 26214416 [TBL] [Abstract][Full Text] [Related]
3. Prediction of occult central lymph node metastasis in papillary thyroid carcinoma by preoperative BRAF analysis using fine-needle aspiration biopsy: a prospective study. Joo JY; Park JY; Yoon YH; Choi B; Kim JM; Jo YS; Shong M; Koo BS J Clin Endocrinol Metab; 2012 Nov; 97(11):3996-4003. PubMed ID: 22930785 [TBL] [Abstract][Full Text] [Related]
5. BRAF V600E mutation: Differential impact on central lymph node metastasis by tumor size in papillary thyroid carcinoma. Kim SK; Lee JH; Woo JW; Park I; Choe JH; Kim JH; Kim JS Head Neck; 2016 Apr; 38 Suppl 1():E1203-9. PubMed ID: 26268700 [TBL] [Abstract][Full Text] [Related]
6. [Study on the correlation between BRAF(V600E) mutation and lymphatic metastases in papillary thyroid cancer staged preoperativelv as N0]. Gao Q; Zhang W; Wang N; Duan H; Zhou Y; Zhang W; Zhao D Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2015 Dec; 29(23):2048-52. PubMed ID: 27101676 [TBL] [Abstract][Full Text] [Related]
7. Chronic lymphocytic thyroiditis and BRAF V600E in papillary thyroid carcinoma. Kim SK; Woo JW; Lee JH; Park I; Choe JH; Kim JH; Kim JS Endocr Relat Cancer; 2016 Jan; 23(1):27-34. PubMed ID: 26598713 [TBL] [Abstract][Full Text] [Related]
8. The synergic effect of BRAF Qu HJ; Qu XY; Hu Z; Lin Y; Wang JR; Zheng CF; Tan Z Endocr J; 2018 Jan; 65(1):113-120. PubMed ID: 29070763 [TBL] [Abstract][Full Text] [Related]
9. Potential relationship between Hashimoto's thyroiditis and BRAF(V600E) mutation status in papillary thyroid cancer. Zeng RC; Jin LP; Chen ED; Dong SY; Cai YF; Huang GL; Li Q; Jin C; Zhang XH; Wang OC Head Neck; 2016 Apr; 38 Suppl 1():E1019-25. PubMed ID: 26041461 [TBL] [Abstract][Full Text] [Related]
11. Risk factors for central lymph node metastasis in patients with papillary thyroid carcinoma: a retrospective study. Du J; Yang Q; Sun Y; Shi P; Xu H; Chen X; Dong T; Shi W; Wang Y; Song Z; Shang X; Tian X Front Endocrinol (Lausanne); 2023; 14():1288527. PubMed ID: 38047112 [TBL] [Abstract][Full Text] [Related]
12. Clinical significance of the BRAF V600E mutation in multifocal papillary thyroid carcinoma in Korea. Ahn HY; Chung YJ; Kim BS; Kang KH; Seok JW; Kim HS; Park SJ; Cho BY Surgery; 2014 Apr; 155(4):689-95. PubMed ID: 24612623 [TBL] [Abstract][Full Text] [Related]
13. Meta-Analyses of Association Between BRAF(V600E) Mutation and Clinicopathological Features of Papillary Thyroid Carcinoma. Zhang Q; Liu SZ; Zhang Q; Guan YX; Chen QJ; Zhu QY Cell Physiol Biochem; 2016; 38(2):763-76. PubMed ID: 26871894 [TBL] [Abstract][Full Text] [Related]
14. Correlation among the BRAF gene mutation status, clinicopathological features of primary tumour, and lymph node metastasizing of papillary thyroid carcinoma. Lukas J; Drabek J; Dudesek B; Vazan P; Stranska J; Jancik S; Mackova M; Syrucek M; Lukas D; Duskova J; Dundr P; Hintnausova B; Jiskra J Exp Clin Endocrinol Diabetes; 2014 May; 122(5):268-72. PubMed ID: 24839220 [TBL] [Abstract][Full Text] [Related]
15. The role of BRAF(V600E) mutation as poor prognostic factor for the outcome of patients with intrathyroid papillary thyroid carcinoma. Pelizzo MR; Dobrinja C; Casal Ide E; Zane M; Lora O; Toniato A; Mian C; Barollo S; Izuzquiza M; Guerrini J; De Manzini N; Merante Boschin I; Rubello D Biomed Pharmacother; 2014 May; 68(4):413-7. PubMed ID: 24721322 [TBL] [Abstract][Full Text] [Related]
16. Predicting factors of central lymph node metastasis and BRAF Zhou SL; Guo YP; Zhang L; Deng T; Xu ZG; Ding C; Sun WC; Zhao YW; Kong LF World J Surg Oncol; 2021 Jul; 19(1):211. PubMed ID: 34256769 [TBL] [Abstract][Full Text] [Related]
17. Combined effect of Hashimoto's thyroiditis and BRAF(V600E) mutation status on aggressiveness in papillary thyroid cancer. Kim SJ; Myong JP; Jee HG; Chai YJ; Choi JY; Min HS; Lee KE; Youn YK Head Neck; 2016 Jan; 38(1):95-101. PubMed ID: 25213729 [TBL] [Abstract][Full Text] [Related]
18. [Clinical pathological characteristics of resectable papillary thyroid microcarcinoma]. Shi CL; Guo Y; Lyu YC; Nanding ZABYS; Gao WC; Shi TF; Qin HD; Liu SY Zhonghua Zhong Liu Za Zhi; 2017 May; 39(5):361-366. PubMed ID: 28535653 [No Abstract] [Full Text] [Related]
19. Role of BRAF V600E mutation as an indicator of the extent of thyroidectomy and lymph node dissection in conventional papillary thyroid carcinoma. Kim SK; Woo JW; Lee JH; Park I; Choe JH; Kim JH; Kim JS Surgery; 2015 Dec; 158(6):1500-11. PubMed ID: 26120069 [TBL] [Abstract][Full Text] [Related]
20. Association of BRAF V600E Mutation and MicroRNA Expression with Central Lymph Node Metastases in Papillary Thyroid Cancer: A Prospective Study from Four Endocrine Surgery Centers. Han PA; Kim HS; Cho S; Fazeli R; Najafian A; Khawaja H; McAlexander M; Dy B; Sorensen M; Aronova A; Sebo TJ; Giordano TJ; Fahey TJ; Thompson GB; Gauger PG; Somervell H; Bishop JA; Eshleman JR; Schneider EB; Witwer KW; Umbricht CB; Zeiger MA Thyroid; 2016 Apr; 26(4):532-42. PubMed ID: 26950846 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]